Conditional License Agreement for mRNA-based ERA Platform… Total $239M
Hanall Biopharma obtains an exclusive license from Daewoong Pharmaceutical for the know-how and patents of the mRNA-based Epigenetic Reprogramming of Aging (ERA) platform, securing rights to research, develop, manufacture, and commercialize in ophthalmic and otic areas
Total deal size is $239 million, consisting of a $1 million upfront payment and $238 million in development milestones; royalties are separate
This is a conditional agreement; the effective date is when agreed conditions between Hanall and Daewoong are met, and the agreement may be terminated if conditions are not fulfilled
The technology is currently in preclinical research stage
The original counterparty changed from Turn Biotechnologies to Daewoong Pharmaceutical (Daewoong acquired Turn's ERA-related assets in May 2026)
KOSPI Filing Information
Filing: [Correction of Description] Report on Major Management Matters Related to Investment Decision